Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Frailty and cardiac rehabilitation: A call to action from the EAPC Cardiac Rehabilitation Section.

Vigorito C, Abreu A, Ambrosetti M, Belardinelli R, Corrà U, Cupples M, Davos CH, Hoefer S, Iliou MC, Schmid JP, Voeller H, Doherty P.

Eur J Prev Cardiol. 2017 Apr;24(6):577-590. doi: 10.1177/2047487316682579. Epub 2016 Dec 11.

PMID:
27940954
2.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators..

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
3.

Travel habits and complications in patients treated with vitamin K antagonists: a cross sectional analysis.

Ringwald J, Lehmann M, Niemeyer N, Seifert I, Daubmann A, Wegscheider K, Salzwedel A, Luxembourg B, Eckstein R, Voeller H.

Travel Med Infect Dis. 2014 May-Jun;12(3):258-63. doi: 10.1016/j.tmaid.2014.02.006. Epub 2014 Mar 12.

PMID:
24657200
4.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators..

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.

5.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators..

Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.

PMID:
19958854
6.

Experience with INR self-management: patient selection and complication rates.

Voeller H, Dovifat C, Wegscheider K.

Z Kardiol. 2005 Dec;94(12):801-7.

PMID:
16382380
7.

Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function.

Gelmann EP, Steadman DJ, Ma J, Ahronovitz N, Voeller HJ, Swope S, Abbaszadegan M, Brown KM, Strand K, Hayes RB, Stampfer MJ.

Cancer Res. 2002 May 1;62(9):2654-9.

8.

Role of cadmium in the regulation of AR gene expression and activity.

Martin MB, Voeller HJ, Gelmann EP, Lu J, Stoica EG, Hebert EJ, Reiter R, Singh B, Danielsen M, Pentecost E, Stoica A.

Endocrinology. 2002 Jan;143(1):263-75.

PMID:
11751618
9.

Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.

Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP.

Cancer Res. 2000 Nov 1;60(21):6111-5.

10.

Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells.

Bowen C, Voeller HJ, Kikly K, Gelmann EP.

Cell Death Differ. 1999 May;6(5):394-401.

11.

Beta-catenin mutations in human prostate cancer.

Voeller HJ, Truica CI, Gelmann EP.

Cancer Res. 1998 Jun 15;58(12):2520-3.

12.

Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers.

Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP.

Cancer Res. 1997 Oct 15;57(20):4455-9. Erratum in: Cancer Res 1997 Dec 15;57(24):5613.

13.

p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.

Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW.

J Natl Cancer Inst. 1997 Jan 1;89(1):66-71.

PMID:
8978408
14.

Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.

Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP.

Cancer Res. 1995 Feb 15;55(4):735-8.

15.

p53 oncogene mutations in human prostate cancer specimens.

Voeller HJ, Sugars LY, Pretlow T, Gelmann EP.

J Urol. 1994 Feb;151(2):492-5.

PMID:
7904314
16.

p53 oncogene mutations in three human prostate cancer cell lines.

Carroll AG, Voeller HJ, Sugars L, Gelmann EP.

Prostate. 1993;23(2):123-34.

PMID:
8104329
17.

v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells.

Voeller HJ, Wilding G, Gelmann EP.

Mol Endocrinol. 1991 Feb;5(2):209-16.

PMID:
2038342

Supplemental Content

Loading ...
Support Center